A background note can be accessed here: India’s Shift to Biopharma Innovation
India currently supplies around 20 percent of global generics and 70 percent of vaccines, yet policy is now pushing toward biosimilars and specialty medicines with higher value addition. How should policymakers navigate the transition from a scale-driven generics model to an innovation-led biopharma strategy without eroding existing comparative advantages?
This transition should not be framed as a shift away from generics. India’s generics sector has created deep capabilities in development efficiency, manufacturing scale, and regulatory execution, which continue to anchor global competitiveness. That base remains important.
The push toward biosimilars and specialty products is logical, but it needs calibration. Innovation-led drug development involves longer timelines, higher capital, and greater risk, which limits its suitability for broad-based scaling. Policymakers should recognise these structural differences while designing incentives.
Biosimilars offer a pragmatic bridge by enabling entry into higher-value segments while drawing on existing strengths. At the same time, instruments like PRIP (Promotion of Research and Innovation in Pharma MedTech Sector) and the RDI (Research, Development and Innovation) scheme should be deployed selectively, with a focus on priority therapeutic areas and platforms rather than diffusing resources.
A disciplined dual-track model is essential. Generics can continue to generate growth and sustain India’s global position, while innovation efforts remain targeted, risk-aware, and strategically prioritised. This balance allows capability expansion without weakening established advantages.
The shift toward biopharma innovation is accompanied by calls for greater R&D investment, industry–academia collaboration, and financing support. To what extent does India’s current innovation ecosystem, spanning regulatory capacity, clinical research infrastructure, and risk capital, align with the requirements of a biopharma-led growth model?
India’s innovation ecosystem shows momentum, but its readiness for a biopharma-led model remains uneven. The country has a strong base in scientific talent and early-stage research, yet the challenge lies in translating discovery into viable products.
The bottleneck sits in the development continuum: IND-enabling studies, CMC processes, PK/PD work, GLP compliance, clinical trials, scalable manufacturing, and regulatory approvals. These stages, where consistency is still evolving, require coordinated infrastructure, execution discipline, and sustained funding.
Policy schemes such as PRIP and RDI signal intent and provide financial support, but ecosystem alignment is equally important. Stronger industry-academia linkages are needed, with early integration of regulatory strategy, clinical positioning, and commercial viability into research design.
Risk capital remains constrained, particularly for mid- and late-stage development where costs escalate sharply and timelines extend. Strengthening this financing layer is critical. Overall, the system is directionally aligned, but the “middle pipeline” that converts scientific promise into approvable therapies needs focused reinforcement.
The move toward biologics, biosimilars, and advanced therapies positions India within high-value global pharmaceutical supply chains, but also increases dependence on complex technologies and intellectual property regimes. How should policymakers balance deeper global integration with the need for strategic autonomy in critical health technologies?
In biologics and advanced therapies, global integration is structurally embedded. These domains rely on complex technologies, specialised knowhow, and intellectual property ecosystems that are distributed internationally. Participation in global networks is therefore essential for capability building and market access.
Strategic autonomy, in this context, should be defined with precision. It involves identifying and strengthening capabilities in areas with clear public health relevance or supply vulnerability, rather than attempting comprehensive self-reliance. Government interventions can play a catalytic role by de-risking early-stage efforts and enabling domestic capacity formation, while maintaining space for private investment and cross-border collaboration.
Operationally, progress will come through a combination of co-development partnerships, licensing arrangements, and targeted technology transfer. This approach allows India to embed itself within global value chains while building depth in selected segments.
A calibrated strategy that is globally engaged and yet remains selectively self-strengthening can support both resilience and competitiveness, ensuring that India remains an active participant in high-value pharmaceutical ecosystems while securing capabilities where they matter most.